Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/86987
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeArtigo de periódicopt_BR
dc.titleThe Real-life Experience With Cardiovascular Complications In The First Dose Of Fingolimod For Multiple Sclerosis [a Experiência Da Vida Real Com Complicações Cardiovasculares Na Primeira Dose De Fingolimode]pt_BR
dc.contributor.authorFragoso Y.D.pt_BR
dc.contributor.authorArruda C.C.pt_BR
dc.contributor.authorArruda W.O.pt_BR
dc.contributor.authorBrooks J.B.B.pt_BR
dc.contributor.authorDamasceno A.pt_BR
dc.contributor.authorDamasceno C.A.A.pt_BR
dc.contributor.authorFinkelsztejn A.pt_BR
dc.contributor.authorFinkelsztejn J.pt_BR
dc.contributor.authorda Gama P.D.pt_BR
dc.contributor.authorGiacomo M.C.B.pt_BR
dc.contributor.authorGomes S.pt_BR
dc.contributor.authorGoncalves M.V.M.pt_BR
dc.contributor.authorMatta A.P.C.pt_BR
dc.contributor.authorde Morais M.M.pt_BR
dc.contributor.authorde Oliveira E.M.L.pt_BR
dc.contributor.authorRibeiro Y.pt_BR
dc.contributor.authorSato H.K.pt_BR
dc.contributor.authorTauil C.B.pt_BR
unicamp.authorDamasceno, A., Departamento de Neurologia, Universidade Estadual de CampinasCampinas, SP, Brazilpt_BR
unicamp.author.externalFragoso, Y.D., Departamento de Neurologia, Universidade Metropolitana de SantosSantos, SP, Brazilpt
unicamp.author.externalArruda, C.C., Departamento de Neurologia, Universidade PositivoCuritiba, PR, Brazilpt
unicamp.author.externalArruda, W.O., Departamento de Neurologia, Universidade Federal do ParanáCuritiba, PR, Brazilpt
unicamp.author.externalBrooks, J.B.B., Departamento de Neurologia, Universidade Metropolitana de SantosSantos, SP, Brazilpt
unicamp.author.externalDamasceno, C.A.A., Departamento de Neurologia, Universidade Federal de Juiz de ForaJuiz de Fora, MG, Brazilpt
unicamp.author.externalFinkelsztejn, A., Departamento de Neurologia, Hospital de Clínicas de Porto AlegrePorto Alegre, RS, Brazilpt
unicamp.author.externalFinkelsztejn, J., Departamento de Neurologia, Hospital de Clínicas de Porto AlegrePorto Alegre, RS, Brazilpt
unicamp.author.externalda Gama, P.D., Departamento de Neurologia, Pontifícia Universidade Católica SorocabaSorocaba, SP, Brazilpt
unicamp.author.externalGiacomo, M.C.B., Clínica Holus MedServiceSao Paulo, SP, Brazilpt
unicamp.author.externalGomes, S., Departamento de Neurologia, Hospital Beneficência Portuguesa de São PauloSao Paulo, SP, Brazilpt
unicamp.author.externalGoncalves, M.V.M., Departamento de Neurologia, Centro Hospitalar UnimedJoinville, SC, Brazilpt
unicamp.author.externalMatta, A.P.C., Departamento de Neurologia, Universidade Federal FluminenseNiterói, RJ, Brazilpt
unicamp.author.externalde Morais, M.M., Departamento de Neurologia, Universidade Federal de São PauloSao Paulo, SP, Brazilpt
unicamp.author.externalde Oliveira, E.M.L., Departamento de Neurologia, Universidade Federal de São PauloSao Paulo, SP, Brazilpt
unicamp.author.externalRibeiro, Y., Departamento de Neurologia, Hospital de Base do Distrito FederalBrasília, DF, Brazilpt
unicamp.author.externalSato, H.K., Departamento de Neurologia, Instituto de Neurologia de CuritibaCuritiba, PR, Brazilpt
unicamp.author.externalTauil, C.B., Departamento de Neurologia, Hospital de Base do Distrito FederalBrasília, DF, Brazilpt
dc.description.abstractFingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.en
dc.relation.ispartofArquivos de Neuro-Psiquiatriapt_BR
dc.publisherAssociacao Arquivos de Neuro-Psiquiatriapt_BR
dc.date.issued2014pt_BR
dc.identifier.citationArquivos De Neuro-psiquiatria. Associacao Arquivos De Neuro-psiquiatria, v. 72, n. 9, p. 712 - 714, 2014.pt_BR
dc.language.isoenpt_BR
dc.description.volume72pt_BR
dc.description.issuenumber9pt_BR
dc.description.firstpage712pt_BR
dc.description.lastpage714pt_BR
dc.rightsabertopt_BR
dc.sourceScopuspt_BR
dc.identifier.issn0004282Xpt_BR
dc.identifier.doi10.1590/0004-282X20140102pt_BR
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84907235996&partnerID=40&md5=f4bd1a510f01313c07f43e30b29185efpt_BR
dc.date.available2015-06-25T17:56:14Z
dc.date.available2015-11-26T14:43:24Z-
dc.date.accessioned2015-06-25T17:56:14Z
dc.date.accessioned2015-11-26T14:43:24Z-
dc.description.provenanceMade available in DSpace on 2015-06-25T17:56:14Z (GMT). No. of bitstreams: 1 2-s2.0-84907235996.pdf: 102372 bytes, checksum: 2f7360a33c8b48036257ab4fa894d1b0 (MD5) Previous issue date: 2014en
dc.description.provenanceMade available in DSpace on 2015-11-26T14:43:24Z (GMT). No. of bitstreams: 2 2-s2.0-84907235996.pdf: 102372 bytes, checksum: 2f7360a33c8b48036257ab4fa894d1b0 (MD5) 2-s2.0-84907235996.pdf.txt: 10599 bytes, checksum: 787d3f4d81b5771f786e54a92e926865 (MD5) Previous issue date: 2014en
dc.identifier.urihttp://www.repositorio.unicamp.br/handle/REPOSIP/86987
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/86987-
dc.identifier.idScopus2-s2.0-84907235996pt_BR
dc.description.referenceThomas, K., Ziemssen, T., Management of fingolimod in clinical practice (2013) Clin Neurol Neurosurg., 115, pp. S60-S64pt_BR
dc.description.referenceOntaneda, D., Hara-Cleaver, C., Rudick, R.A., Cohen, J.A., Bermel, R.A., Early tolerability and safety of fingolimod in clinical practice (2012) J Neurol Sci., 323, pp. 167-172pt_BR
dc.description.referenceBünemann, M., Liliom, K., Brandts, B.K., A novel membrane receptor with high affinity for lysosphingomyelin and sphingosine 1-phosphate in atrial myocytes (1996) EMBO J., 15, pp. 5527-5534pt_BR
dc.description.referenceSanna, M., Liao, J., Jo, E., Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate (2004) J Biol Chem, 279, pp. 13839-13848pt_BR
dc.description.referenceLaroni, A., Brogi, D., Morra, V.B., Safety of the first dose of fingolimod for multiple sclerosis: Results of an open-label clinical trial (2014) BMC Neurol, 14, p. 65pt_BR
dc.description.referencePolman, C.H.R., Reingold, S.C., Banwell, B., Dianosticcriteria for multiple sclerosis: 2010 Revisions to the Mac Donald criteria (2011) Ann Neurol, 69, pp. 292-302pt_BR
dc.description.referenceEspinosa, P.S., Berger, J.R., Delayed fingolimod-associated asystole (2011) Mult Scler, 17, pp. 1387-1389pt_BR
dc.description.referenceKappos, L., Radue, E.W., O'Connor, P., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis (2010) N Engl J Med, 362, pp. 387-401pt_BR
dc.description.referenceSinger, B.A., Initiating oral fingolimod treatment in patients with multiple sclerosis (2013) Ther Adv Neurol Disord, 6, pp. 269-275pt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-84907235996.pdf99.97 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.